SAB Biotherapeutics, Inc. (SABS) stock intrinsic value fair value estimate & owner earnings analysis

SAB Biotherapeutics is a clinical-stage drug developer with no product sales. Its platform uses genetically engineered cattle, which it calls Tc Bovine, that produce human antibodies: the animals are immunized against a chosen target and the human antibodies are collected from their plasma and purified. The company is now focused on one candidate, SAB-142, a human polyclonal antibody aimed at the T-lymphocytes that destroy insulin-producing beta cells in type 1 diabetes. After a Phase 1 trial with positive topline data reported in January and December 2025, it began a global, placebo-controlled Phase 2b trial called SAFEGUARD and dosed its first patient in December 2025. The trial is designed to enroll 159 patients aged 5 to 40 with newly diagnosed (Stage 3) type 1 diabetes, and the company expects topline data in the second half of 2027. The company intends the study to serve as primary evidence for approval, but its annual report warns the FDA may require additional supportive trials. Track record. The company booked $55.2 million of revenue in 2020 and $60.9 million in 2021, mostly from US government grants and contracts. That work has ended: revenue fell to $23.9 million in 2022, $2.2 million in 2023, $1.3 million in 2024 and zero in 2025. Owner earnings (cash from operations after stripping out working-capital swings, stock-based pay and equipment upkeep) were positive only in 2020, at about $7.9 million. Since then the business has consumed about $22 million in 2021, $28 million in 2022, $34 million in 2023, $35 million in 2024 and $47 million in 2025. The reported 2025 net profit of $13.3 million is an accounting effect of a $62.8 million non-cash gain from revaluing warrants, which we excluded. We count stock-based pay as a real cost because it dilutes owners, and in 2023 we also counted $3.9 million of professional fees paid in stock. Spending has stepped up with the Phase 2b trial. In the first half of 2026, operating cash outflow was $24.1 million, equipment spending $2.6 million (the company is establishing a second, redundant animal facility) and stock-based pay $12.7 million, together about $39 million for six months. Research and development spending in the second quarter of 2026 was $16.2 million against $7.0 million a year earlier, and the operating loss rose from $20.0 million in the first quarter to $23.4 million in the second. Because two consecutive quarters show the higher rate, we use it rather than the smaller losses of earlier years. The full-cost loss widened about 34% in 2025; our base case has it widening further to about $85 million a year, which the first half of 2026 already supports. Balance sheet. At June 30, 2026 the company held $208.0 million of cash and investments, funded chiefly by a $175 million private placement of convertible preferred stock and warrants that closed in July 2025. Its only borrowing is a $3.2 million finance lease, leaving about $205 million of net cash. Counting the convertible preferred as common shares there were about 116 million shares at the end of 2025; we use about 118 million, allowing for warrant exercises that brought in $3.5 million in the first half of 2026. Options and awards over about 20.9 million shares and other warrants over about 19 million shares outstanding at the end of 2025 are not included in that count. How we value it. SAB-142 has no approval, no partner and no contract that would pay the company, so we give the pipeline no value in any case. That is not a prediction that the trial will fail; it is that nothing in the filings yet shows what the drug would earn. What can be valued is the cash the company holds and the cost of the program it is running. Each case runs until the SAFEGUARD readout, where the story either changes or ends, and discounts that spending at 6% a year. Bull case ($0.93 a share): topline data arrive on the stated schedule, about 15 months from mid-2026, with spending held at the first-half 2026 pace of about $79 million a year including stock pay. The program costs about $95 million in today's money; subtracting that and the $3.2 million lease from $208.0 million of cash leaves about $110 million for shareholders. Base case ($0.70): readout by the end of 2027, 18 months out, with spending near $85 million a year, between the first- and second-quarter 2026 rates. The program costs about $122 million in today's money, leaving about $83 million after the $3.2 million lease. Bear case (-$0.10): the FDA asks for additional supportive evidence, as the annual report warns it may, and spending runs for 30 months at the second-quarter 2026 pace of roughly $93 million a year. That costs about $216 million in today's money, roughly $12 million more than the $205 million of net cash. We assume about $170 million of it would be cash and the rest stock pay, so the company would not literally run dry, but the gap would be filled by issuing new shares and today's holders would be left with slightly less than nothing on this path. Warrants. The July 2025 investors also hold warrants to buy more preferred stock, equal to about 150 million common shares at $1.75 and $2.19 a share (about $284 million in total). They lapse if not exercised by the time the trial is fully enrolled or its topline data are released. Exercise would bring in cash at prices above our per-share values and would raise them, but it is the investors' choice and depends on how the trial is going, so we leave it out of every case. What would make this wrong. A positive SAFEGUARD readout, or a partnership paying cash for SAB-142 or the antibody platform, would create value this analysis deliberately does not count. On the other side, spending faster than the second-quarter 2026 pace or a delayed readout would shrink what is left for shareholders. With a binary outcome and cash being consumed, the margin-of-safety price is set at roughly half the base case.